<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140810018754N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-11-03</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effects of high intensity laser therapy on knee ostoarthrosis</public_title>
      <acronym></acronym>
      <scientific_title>The effects of High Intensity Laser Therapy(HILT) in comparison with Intra Articular Hyaluronic Acid(IAHA)  injection on the pain and function of knee ostoarthrosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-09-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33711</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization
Unit of randomization: personal
Using the SPSS program, Blinding description: Examiner did not know that each simple present in witch group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Knee ostoarthrosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: This group constitutes patients with  knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, whom received weekly (more accurately, for times a week) hyaluronic acid injection. The patients are to be undergone physiotherapy simultaneous with their getting the injections. the physiotherapy treatment comprises 20-minute IF current , US  applied continuous  for 5 minutes with 1 W/cm2 intensity, IR for 15 minutes, as well as the exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions. Intervention 2: Intervention group 2: This group constitutes patients with knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, receiving physiotherapy treatment as well as High Intensity Laser Therapy(HILT) . the laser's treatment protocol in the first three sessions is as follows: duty cycle:50%, frequency: 5000 Hz, Power density2.04 W, Energy density 10 J/cm2, treatment duration: 3 minute, the approximate treatment area : 100cm2 round the knee and the total apleid energy is 1000 J. However, the laser's treatment protocol in the next seven sessions is as follows:Power density 4.09 W, Energy density 50 J/cm2, treatment duration: 7 minute, the approximate treatment area : 100cm2 round the knee, the total apleid energy is 5000 J. and the laser's wavelength is 980 nm. The physiography treatment of this group comprises, as does the invention group 1,  20-minute IF current , US  applied continuous for 5 minutes with 1 W/cm2 intensity, IR for 15 minutes, as well as the  exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions. Intervention 3: Control group:  This group constitutes patients with knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, receiving physiotherapy treatment as well as placebo High Intensity Laser Therapy  (HILT), that is to say, the treatment is performed in a similar manner as to intervention group 2 ,though the laser fluency is lacking. As was the case for intervention group 1 and 2,  the physiography treatment of this group comprises 20-minute IF current , US  applied continuous  for 5 minutes with 1 W/cm2 intensity, as well as the exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data or results of the present study will be presented in an article or some articles that will be published after completing the study.

When:
After completing the present study and publishing the resulting article or articles.

To whom:
All researchers in the field of the present study.

Conditions:
With the same goal as the present study and with mention of the present study as the reference. All intellectual property rights of the present study belongs to the Iran University of Medical Sciences.

Where to obtain:
The corresponding author of the article or articles derived from this study.

How to obtain:
Written request from the author responsible for the present review after the publication of the resulting article or articles.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Javad Sarrafzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physiotherapy department, School of Rehabilitation Sciences, Madadkaran street., Shahnazari street, Madar squ., Mirdamad street.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15459-13487</zip>
        <telephone>+98 21 2222 8051</telephone>
        <email>sarrafzadeh.j@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Javad Sarrafzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physiotherapy department, School of Rehabilitation Sciences, Madadkaran street., Shahnazari street, Madar squ., Mirdamad street.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15459-13487</zip>
        <telephone>+98 21 2222 8051</telephone>
        <email>sarrafzadeh.j@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Grade 1 or 2 knee osteoarthritis according to the Kellgren-Lawrence classification
had a knee pain≥4 on the visual analog scale (VAS)
do not injection corticostroid or hyaluronic acid in last six mount
the gain 25 number in minimum condition from the WOMAC scale
BMI &lt; 30</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>existence RA, malignancy, knee surgery, fracture, menisqe or ligament tearing, genu varum or valgum above 20 degree, referal pain from hip or lumbar region
doing physiotherapy in last six mount</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: This group constitutes patients with  knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, whom received weekly (more accurately, for times a week) hyaluronic acid injection. The patients are to be undergone physiotherapy simultaneous with their getting the injections. the physiotherapy treatment comprises 20-minute IF current , US  applied continuous  for 5 minutes with 1 W/cm2 intensity, IR for 15 minutes, as well as the exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions.</i_keyword>
      <i_keyword>Intervention group 2: This group constitutes patients with knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, receiving physiotherapy treatment as well as High Intensity Laser Therapy(HILT) . the laser's treatment protocol in the first three sessions is as follows: duty cycle:50%, frequency: 5000 Hz, Power density2.04 W, Energy density 10 J/cm2, treatment duration: 3 minute, the approximate treatment area : 100cm2 round the knee and the total apleid energy is 1000 J. However, the laser's treatment protocol in the next seven sessions is as follows:Power density 4.09 W, Energy density 50 J/cm2, treatment duration: 7 minute, the approximate treatment area : 100cm2 round the knee, the total apleid energy is 5000 J. and the laser's wavelength is 980 nm. The physiography treatment of this group comprises, as does the invention group 1,  20-minute IF current , US  applied continuous for 5 minutes with 1 W/cm2 intensity, IR for 15 minutes, as well as the  exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions.</i_keyword>
      <i_keyword>Control group:  This group constitutes patients with knee arthrosis, on the basis of Kellgren- Lawrence classification grade 1 or 2, receiving physiotherapy treatment as well as placebo High Intensity Laser Therapy  (HILT), that is to say, the treatment is performed in a similar manner as to intervention group 2 ,though the laser fluency is lacking. As was the case for intervention group 1 and 2,  the physiography treatment of this group comprises 20-minute IF current , US  applied continuous  for 5 minutes with 1 W/cm2 intensity, as well as the exercise training. The physiotherapy treatment must be performed weekly (triple a week) for 10 sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of pain. Timepoint: before starting the first treatment session, after the end of treatment session and one mount after the last of treatment session. Method of measurement: Visual analog scale (VAS).</prim_outcome>
      <prim_outcome>Function and quality of life. Timepoint: before starting the first treatment session, after the end of treatment session and one mount after the last of treatment session. Method of measurement: persian WOMAC scal.</prim_outcome>
      <prim_outcome>Rang of motion of knee FLX and EXT. Timepoint: before starting the first treatment session, after the end of treatment session and one mount after the last of treatment session. Method of measurement: KROM device (degree).</prim_outcome>
      <prim_outcome>Amount of knee odema. Timepoint: before starting the first treatment session, after the end of treatment session and one mount after the last of treatment session. Method of measurement: tape measure according in CM.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-08-25</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>5th floor, Iran University of Medical Sciences, Hemmat highway, between Sheikh Fazlollah Nuri and Chamran highways. tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
